Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 8Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Fallopian Tube Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 4Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Glioblastoma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary leiomyomatosis and renal cell cancer × Immunoglobulin G × 90 days × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡